Shenzhen Salubris Pharmaceuticals Co., Ltd.

SZSE:002294 Stock Report

Market Cap: CN¥35.7b

Shenzhen Salubris Pharmaceuticals Future Growth

Future criteria checks 2/6

Shenzhen Salubris Pharmaceuticals is forecast to grow earnings and revenue by 15.5% and 14.9% per annum respectively. EPS is expected to grow by 15.5% per annum. Return on equity is forecast to be 9.2% in 3 years.

Key information

15.5%

Earnings growth rate

15.5%

EPS growth rate

Pharmaceuticals earnings growth19.4%
Revenue growth rate14.9%
Future return on equity9.2%
Analyst coverage

Low

Last updated29 Oct 2024

Recent future growth updates

Recent updates

These 4 Measures Indicate That Shenzhen Salubris Pharmaceuticals (SZSE:002294) Is Using Debt Safely

Nov 11
These 4 Measures Indicate That Shenzhen Salubris Pharmaceuticals (SZSE:002294) Is Using Debt Safely

We Think That There Are More Issues For Shenzhen Salubris Pharmaceuticals (SZSE:002294) Than Just Sluggish Earnings

Sep 02
We Think That There Are More Issues For Shenzhen Salubris Pharmaceuticals (SZSE:002294) Than Just Sluggish Earnings

What Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) P/E Is Not Telling You

Aug 23
What Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) P/E Is Not Telling You

Are Investors Undervaluing Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) By 21%?

Aug 02
Are Investors Undervaluing Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) By 21%?

Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Share Price Not Quite Adding Up

May 22
Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Share Price Not Quite Adding Up

A Look At The Fair Value Of Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294)

Apr 17
A Look At The Fair Value Of Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294)

Is Shenzhen Salubris Pharmaceuticals (SZSE:002294) A Risky Investment?

Feb 28
Is Shenzhen Salubris Pharmaceuticals (SZSE:002294) A Risky Investment?

Earnings and Revenue Growth Forecasts

SZSE:002294 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20265,4408587271,2014
12/31/20254,6087336508624
12/31/20244,0506334651,0052
9/30/20243,9106115611,158N/A
6/30/20243,7245872891,019N/A
3/31/20243,569569262944N/A
12/31/20233,365580168839N/A
9/30/20233,390577121806N/A
6/30/20233,498627388916N/A
3/31/20233,434611402931N/A
1/1/20233,482637372971N/A
9/30/20223,4196814811,032N/A
6/30/20223,3506457681,276N/A
3/31/20223,2286167261,231N/A
1/1/20223,0585347021,185N/A
9/30/20212,7921855101,063N/A
6/30/20212,57910140597N/A
3/31/20212,63866341878N/A
12/31/20202,739617321,374N/A
9/30/20203,0412668111,408N/A
6/30/20203,6502791,1711,774N/A
3/31/20204,1485441,0431,680N/A
12/31/20194,4707151,0491,507N/A
9/30/20194,6811,0251,0671,479N/A
6/30/20194,7411,3011,2381,599N/A
3/31/20194,7141,3641,1781,475N/A
12/31/20184,6521,4581,0081,341N/A
9/30/20184,5871,5081,1741,494N/A
6/30/20184,3861,511N/A1,280N/A
3/31/20184,3081,491N/A1,336N/A
12/31/20174,1541,452N/A1,458N/A
9/30/20174,1061,451N/A1,406N/A
6/30/20173,9761,432N/A1,507N/A
3/31/20173,8911,415N/A1,557N/A
12/31/20163,8331,396N/A1,435N/A
9/30/20163,7391,380N/A1,503N/A
6/30/20163,7111,341N/A1,340N/A
3/31/20163,6101,310N/A1,170N/A
12/31/20153,4781,266N/A1,056N/A
9/30/20153,4671,217N/A972N/A
6/30/20153,2371,166N/A921N/A
3/31/20153,0151,102N/A978N/A
12/31/20142,8831,042N/A982N/A
9/30/20142,686989N/A877N/A
6/30/20142,570933N/A909N/A
3/31/20142,450883N/A761N/A
12/31/20132,327830N/A669N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 002294's forecast earnings growth (15.5% per year) is above the savings rate (2.8%).

Earnings vs Market: 002294's earnings (15.5% per year) are forecast to grow slower than the CN market (26.5% per year).

High Growth Earnings: 002294's earnings are forecast to grow, but not significantly.

Revenue vs Market: 002294's revenue (14.9% per year) is forecast to grow faster than the CN market (14.1% per year).

High Growth Revenue: 002294's revenue (14.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 002294's Return on Equity is forecast to be low in 3 years time (9.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y